Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The How: Evidence-Based Testing Strategies to Detect Appropriate Gene Alterations (39 mins)

Gain insights from Laura J. Tafe, MD, a molecular pathologist, on best practices for biomarker testing in lung cancer.
Nathan Pennell, MD, PhD
Laura J. Tafe, MD
Released: January 15, 2021 Expiration: No longer available for credit

This program is divided into several short segments that you can step through using the Video Chapters menu.

Related Content

Downloadable slides on managing adverse events associated with asparaginase-based therapy in patients with ALL, from Clinical Care Options (CCO)

Emily Curran, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors in relapsed/refractory CLL/SLL, from Clinical Care Options (CCO).

Jeff Sharman, MD Released: December 9, 2022

Downloadable slideset on BTK inhibitors for the frontline treatment of CLL/SLL from Clinical Care Options (CCO).

Susan M. O'Brien, MD Released: December 9, 2022

Downloadable slideset from Dr. Eytan M. Stein on selecting therapy for AML patients with predictive biomarkers or actionable alterations, from Clinical Care Options (CCO)

Eytan M. Stein, MD Released: December 9, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings